Dan Feng
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases (NCT07277322) | Dan Feng | 2026-09-01 |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC (NCT07281716) | Dan Feng | 2025-12-01 |
Track Dan Feng automatically
Every clearance here is in the API, with alerts when new ones post.